Tumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients

Er Chieh Cho, Mei Ling Kuo, Xiyong Liu, Lixin Yang, Yi Chen Hsieh, Jinghan Wang, Yawen Cheng, Yun Yen

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The role of Ribonucleotide reductase (RR) subunits in different cancers has been intensively studied in our laboratory. RRM2B was identified as a p53-inducible RR subunit that involves in various critical cellular mechanisms such as cell cycle regulation, DNA repair and replication, and mitochondrial homeostasis, etc. However, little is known about the p53-independent regulation of RRM2B in cancer pathology. In this study, we discovered tumor suppressor FOXO3 as the novel regulator of RRM2B. FOXO3 directly bound to and transcriptionally activated the promoter of RRM2B, and induced the expression of RRM2B at RNA and protein levels. Moreover, Overexpression of RRM2B and/or FOXO3 inhibited the proliferation of cancer cells. The cancer tissue microarray data also demonstrated a strong correlation between the co-expression of FOXO3 plus RRM2B and increased disease survival and reduced recurrence or metastasis in lung cancer patients. Our results suggest a novel regulatory control of RRM2B function, and imply the importance of FOXO signaling pathway in DNA replication modulation. This study provides the first time evidence that RRM2B is transcriptionally and functionally regulated independent of p53 pathway by FOXO3, and it establishes that FOXO3 and RRM2B could be used as predictive biomarkers for cancer progression.

Original languageEnglish
Pages (from-to)4834-4844
Number of pages11
JournalOncotarget
Volume5
Issue number13
Publication statusPublished - 2014

Fingerprint

Ribonucleotide Reductases
Survival
Neoplasms
DNA Replication
Tumor Biomarkers
DNA Repair
Lung Neoplasms
Cell Cycle
Homeostasis
Cell Proliferation
RNA
Pathology
Neoplasm Metastasis
Recurrence
Proteins

Keywords

  • Biomarker
  • Cancer
  • RRM2B
  • Tumor suppressor FOXO3

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Tumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients. / Cho, Er Chieh; Kuo, Mei Ling; Liu, Xiyong; Yang, Lixin; Hsieh, Yi Chen; Wang, Jinghan; Cheng, Yawen; Yen, Yun.

In: Oncotarget, Vol. 5, No. 13, 2014, p. 4834-4844.

Research output: Contribution to journalArticle

Cho, Er Chieh ; Kuo, Mei Ling ; Liu, Xiyong ; Yang, Lixin ; Hsieh, Yi Chen ; Wang, Jinghan ; Cheng, Yawen ; Yen, Yun. / Tumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients. In: Oncotarget. 2014 ; Vol. 5, No. 13. pp. 4834-4844.
@article{2a93e00c674648078a219f457d2a9951,
title = "Tumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients",
abstract = "The role of Ribonucleotide reductase (RR) subunits in different cancers has been intensively studied in our laboratory. RRM2B was identified as a p53-inducible RR subunit that involves in various critical cellular mechanisms such as cell cycle regulation, DNA repair and replication, and mitochondrial homeostasis, etc. However, little is known about the p53-independent regulation of RRM2B in cancer pathology. In this study, we discovered tumor suppressor FOXO3 as the novel regulator of RRM2B. FOXO3 directly bound to and transcriptionally activated the promoter of RRM2B, and induced the expression of RRM2B at RNA and protein levels. Moreover, Overexpression of RRM2B and/or FOXO3 inhibited the proliferation of cancer cells. The cancer tissue microarray data also demonstrated a strong correlation between the co-expression of FOXO3 plus RRM2B and increased disease survival and reduced recurrence or metastasis in lung cancer patients. Our results suggest a novel regulatory control of RRM2B function, and imply the importance of FOXO signaling pathway in DNA replication modulation. This study provides the first time evidence that RRM2B is transcriptionally and functionally regulated independent of p53 pathway by FOXO3, and it establishes that FOXO3 and RRM2B could be used as predictive biomarkers for cancer progression.",
keywords = "Biomarker, Cancer, RRM2B, Tumor suppressor FOXO3",
author = "Cho, {Er Chieh} and Kuo, {Mei Ling} and Xiyong Liu and Lixin Yang and Hsieh, {Yi Chen} and Jinghan Wang and Yawen Cheng and Yun Yen",
year = "2014",
language = "English",
volume = "5",
pages = "4834--4844",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "13",

}

TY - JOUR

T1 - Tumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients

AU - Cho, Er Chieh

AU - Kuo, Mei Ling

AU - Liu, Xiyong

AU - Yang, Lixin

AU - Hsieh, Yi Chen

AU - Wang, Jinghan

AU - Cheng, Yawen

AU - Yen, Yun

PY - 2014

Y1 - 2014

N2 - The role of Ribonucleotide reductase (RR) subunits in different cancers has been intensively studied in our laboratory. RRM2B was identified as a p53-inducible RR subunit that involves in various critical cellular mechanisms such as cell cycle regulation, DNA repair and replication, and mitochondrial homeostasis, etc. However, little is known about the p53-independent regulation of RRM2B in cancer pathology. In this study, we discovered tumor suppressor FOXO3 as the novel regulator of RRM2B. FOXO3 directly bound to and transcriptionally activated the promoter of RRM2B, and induced the expression of RRM2B at RNA and protein levels. Moreover, Overexpression of RRM2B and/or FOXO3 inhibited the proliferation of cancer cells. The cancer tissue microarray data also demonstrated a strong correlation between the co-expression of FOXO3 plus RRM2B and increased disease survival and reduced recurrence or metastasis in lung cancer patients. Our results suggest a novel regulatory control of RRM2B function, and imply the importance of FOXO signaling pathway in DNA replication modulation. This study provides the first time evidence that RRM2B is transcriptionally and functionally regulated independent of p53 pathway by FOXO3, and it establishes that FOXO3 and RRM2B could be used as predictive biomarkers for cancer progression.

AB - The role of Ribonucleotide reductase (RR) subunits in different cancers has been intensively studied in our laboratory. RRM2B was identified as a p53-inducible RR subunit that involves in various critical cellular mechanisms such as cell cycle regulation, DNA repair and replication, and mitochondrial homeostasis, etc. However, little is known about the p53-independent regulation of RRM2B in cancer pathology. In this study, we discovered tumor suppressor FOXO3 as the novel regulator of RRM2B. FOXO3 directly bound to and transcriptionally activated the promoter of RRM2B, and induced the expression of RRM2B at RNA and protein levels. Moreover, Overexpression of RRM2B and/or FOXO3 inhibited the proliferation of cancer cells. The cancer tissue microarray data also demonstrated a strong correlation between the co-expression of FOXO3 plus RRM2B and increased disease survival and reduced recurrence or metastasis in lung cancer patients. Our results suggest a novel regulatory control of RRM2B function, and imply the importance of FOXO signaling pathway in DNA replication modulation. This study provides the first time evidence that RRM2B is transcriptionally and functionally regulated independent of p53 pathway by FOXO3, and it establishes that FOXO3 and RRM2B could be used as predictive biomarkers for cancer progression.

KW - Biomarker

KW - Cancer

KW - RRM2B

KW - Tumor suppressor FOXO3

UR - http://www.scopus.com/inward/record.url?scp=84905001944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905001944&partnerID=8YFLogxK

M3 - Article

C2 - 24947616

AN - SCOPUS:84905001944

VL - 5

SP - 4834

EP - 4844

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 13

ER -